产品说明书

Pimavanserin

Print
Chemical Structure| 706779-91-1 同义名 : ACP-103
CAS号 : 706779-91-1
货号 : A754938
分子式 : C25H34FN3O2
纯度 : 98%
分子量 : 427.555
MDL号 : MFCD09953792
存储条件：

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(116.94 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Pimavanserin is a potent and selective 5-HT2A receptor inverse agonist with mean pIC50 of with 8.7 in the cell-based functional assay.
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00086294 Parkinson's Disease ... 展开 >> Dyskinesias 收起 << Phase 2 Completed - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT03152292 - Recruiting September 2021 -
NCT00087542 Hallucinations ... 展开 >> Psychoses Parkinson's Disease 收起 << Phase 2 Completed - United States, California ... 展开 >> Fountain Valley, California, United States, 92708 Sunnyvale, California, United States, 94089 United States, Connecticut Danbury, Connecticut, United States, 06810 United States, Florida Pompano Beach, Florida, United States, 33060 Tampa, Florida, United States, 33606 United States, Georgia Atlanta, Georgia, United States, 30329 United States, Kansas Kansas City, Kansas, United States, 66160 United States, Maryland Elkridge, Maryland, United States, 21075 United States, New York Albany, New York, United States, 12205 United States, North Carolina Asheville, North Carolina, United States, 28806 United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19107 United States, Rhode Island Pawtucket, Rhode Island, United States, 02860 United States, Tennessee Brentwood, Tennessee, United States, 37027 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.34mL

0.47mL

0.23mL

11.69mL

2.34mL

1.17mL

23.39mL

4.68mL

2.34mL
参考文献

[1]Vanover KE, Betz AJ, et al. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav. 2008 Oct;90(4):540-4.

[2]Vanover KE, Weiner DM, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May;317(2):910-8.